Abstract Library

#1277 Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors

Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Sansovini M

Authors: Sansovini M, Severi S, Nicolini S, Ianniello A, Ambrosetti A,

Keywords: PRRT, FDG-PET, P-NET,

#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs

Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Severi S

Authors: Stefano S, Maddalena S, Ianniello A, Nicolini S, Caroli P,

Keywords: PRRT, GEP-NET, re-treatment,

#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).

Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Sansovini M

Authors: Sansovini M, Stefano S, Ianniello A, Nicolini S, Fantini L,

Keywords: PRRT, neuroendocrine, FDG-PET,

#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Sansovini M, Severi S, Ambrosetti A, Monti M, Nanni O,

Keywords: neuroendocrine, peptide receptor radionuclide therapy,